Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Letters to the Editor

Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation

Bone Marrow Transplantation volume 51, pages 1387–1390 (2016)Cite this article

Subjects

Non-myeloablative hemopoietic stem cell transplantation (NM-HSCT) is often the only curative treatment option for patients with hematologic malignancies.1 However, the treatment is frequently complicated by significant morbidity and mortality, acute GvHD (aGvHD) and chronic GvHD (cGvHD) being among the major causes.2

The pathophysiology of aGvHD is complex and can be summarized as a three-step process including (i) activation of APCs, (ii) donor T-cell activation and (iii) target tissue destruction.3 On the contrary, the pathophysiology of cGvHD is poorly understood, although abnormalities in B-cell and T-cell functions, including alterations in the function of Th1, Th2 and regulatory T (Tregs; CD4+CD25+FoxP3+) cells, have been hypothesized to result in a global loss of immune tolerance.4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.

    Article  CAS  Google Scholar 

  2. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874–1883.

    Article  CAS  Google Scholar 

  3. Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.

    Article  CAS  Google Scholar 

  4. Linhares YP, Pavletic S, Gale RP . Chronic GVHD: where are we? where do we want to be? will immunomodulatory drugs help? Bone Marrow Transplant 2013; 48: 203–209.

    Article  CAS  Google Scholar 

  5. Rabinovich GA, Toscano MA . Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9: 338–352.

    Article  CAS  Google Scholar 

  6. Baum LG, Blackall DP, Arias-Magallano S, Nanigian D, Uh SY, Browne JM et al. Amelioration of graft versus host disease by galectin-1. Clin Immunol 2003; 109: 295–307.

    Article  CAS  Google Scholar 

  7. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007; 8: 825–834.

    Article  CAS  Google Scholar 

  8. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 2013; 73: 1107–1117.

    Article  CAS  Google Scholar 

  9. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003; 88: 132–135.

    Article  CAS  Google Scholar 

  10. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  11. Rabinovich GA, Croci DO . Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36: 322–335.

    Article  CAS  Google Scholar 

  12. Croci DO, Cerliani JP, Pinto NA, Morosi LG, Rabinovich GA . Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment. Glycobiology 2014; 24: 1283–1290.

    Article  CAS  Google Scholar 

  13. Henden AS, Hill GR . Cytokines in graft-versus-host disease. J Immunol 2015; 194: 4604–4612.

    Article  CAS  Google Scholar 

  14. Xu G, Tu W, Xu C . Immunological tolerance induced by galectin-1 in rat allogeneic renal transplantation. Int Immunopharmacol 2010; 10: 643–647.

    Article  CAS  Google Scholar 

  15. Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 10: 981–991.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank professor Peter Hokland for significant support and advice, and professor Jan Frystyk, Aarhus University Hospital, Aarhus, Denmark for fruitful discussions on the Gal-1 time-resolved immunofluorometric assay. The present study was supported by the funding from Health Research Fund of Central Denmark Region, the Karen Elise Jensen’s Foundation, the Max and Inger Wørzner Foundation, Meta and Håkon Baggers Foundation, King Christian X Foundation, Harboe Foundation, Manufacturer Einer Willumsens Memorial Trust, Krista and Viggo Petersens Foundation, A.P. Møller Foundation and Dagmar Marshhalls Foundation.

Author contributions

IP and FdA designed and coordinated the study, performed statistical analysis and wrote the manuscript; MV and PK assisted/advised in the performance of statistical analyses; ML, BH and RH performed and evaluated Gal-1 analysis; BSS collected and provided serum samples; BN advised during the design of the study and GAR critically reviewed the manuscript. All authors reviewed the manuscript and approved its final version.

Author information

Authors and Affiliations

  1. Department of Haematology, Aarhus University Hospital, Aarhus, Denmark

    I Petruskevicius, P Kamper, M Vase, L G Oestgaard, B Nielsen & F A d'Amore

  2. Department of Biomedicine, Aarhus University, Aarhus, Denmark

    M Ludvigsen & B Honoré

  3. Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark

    R Hjortebjerg & M Bjerre

  4. Department of Immunology, Aarhus University Hospital, Aarhus, Denmark

    B S Sørensen

  5. Institute of Biology and Experimental Medicine (IBYME), National Council Research (CONICET) and School of Exact and Natural Sciences, University of Buenos,

    G A Rabinovich

  6. Aires, Buenos Aires, Argentina

    G A Rabinovich

Authors
  1. I Petruskevicius
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Ludvigsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Hjortebjerg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B S Sørensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Kamper
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Vase
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L G Oestgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B Honoré
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Bjerre
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G A Rabinovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F A d'Amore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F A d'Amore.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petruskevicius, I., Ludvigsen, M., Hjortebjerg, R. et al. Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation. Bone Marrow Transplant 51, 1387–1390 (2016). https://doi.org/10.1038/bmt.2016.127

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.127

Search

Advanced search

Quick links